Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
Provided By GlobeNewswire
Last update: Mar 27, 2025
CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
Read more at globenewswire.com2.5
+0.37 (+17.37%)
Find more stocks in the Stock Screener
SPRO Latest News and Analysis
2 days ago - ChartmillUnusual volume stocks in Friday's sessionLet's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session.
3 days ago - ChartmillThe trading volume of these stocks is deviating from the norm in today's session.Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.
3 days ago - ChartmillThese stocks are making the most noise in today's session.Let's dive into the action on the US markets on Wednesday. Here are the most active stocks that are driving the market today.
